Serum percent free prostate-specific antigen in metastatic prostate cancer

Urology

Volumn 52, Issue 3, 1998, Pages 366-371

  Lin, Daniel W ^a   Noteboom, Jennifer L ^a   Blumenstein, Brent A ^a   Ellis, William J ^a   Lange, Paul H ^a   Vessella, Robert L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; FOLLOW UP; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0032167690     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00240-4     Document Type: Article

References (30)

1. 1. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
2. 2. Wang M, Valenzuela L, Murphy G, et al: Purification of human prostate specific antigen. Invest Urol 17: 159-163, 1979.
3. 3. Catalona WJ, Richie JP, Ahmann FR, et al: Comparison of DRE and serum PSA in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290, 1994.
4. 4. Brawer MK, Beattie J, Wener MH, et al: Screening for prostatic carcinoma with PSA: results of the second year. J Urol 150: 106-109, 1993.
5. 5. Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through PSA-based screening. JAMA 270: 948-954, 1993.
6. 6. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum PSA in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
7. 7. Smith DS, and Catalona WJ: Rate of change in serum prostate-specific antigen levels as a method for prostate cancer detection. J Urol 152: 1163-1167, 1994.
8. 8. Kalish J, Cooner WH, and Graham SD: Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43: 601-606, 1994.
9. 9. Lilja H, Christensson A, Dahlen U, et al: PSA in human serum occurs predominantly in complex with alpha-1 antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
10. 10. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum PSA to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
11. 11. Partin AW, Catalona WJ, Southwick PC, et al: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48: 55-61, 1996.
12. 12. Catalona WJ, Beiser JA, and Smith DS: Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 158: 2162-2167, 1997.
13. 13. Prestigiacomo AF, and Stamey TA: Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol 157: 189-194, 1997.
14. 14. Vashi AR, Wojno KJ, Henricks W, et al: Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 49: 19-27, 1997.
15. 15. Jacobsen LJ, Klee GG, Lilja H, et al: Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology 45: 447-453, 1995.
16. 16. Arcangeli CG, Smith DS, Ratliff TL, et al: Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol 158: 2182-2187, 1997.
17. 17. Partin AW, Yoo J, Carter HB, et al: The use of PSA, clinical stage and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 150: 110-114, 1993.
18. 18. Van Cangh PJ, De Nayer P, Sauvage P, et al: Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate 7(suppl): 30-34, 1996.
19. 19. Luderer AA, Chen YT, Suriano TF, et al: Measurement of the proportion of free and total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
20. 20. Carter HB, Partin AW, Luderer AA, et al: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49: 379-384, 1997.
21. 21. Arcangeli CG, Humphrey PA, Smith DS, et al: Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 51: 558-565, 1998.
22. 22. Lerner SE, Jacobsen SJ, Lilja H, et al: Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology 42: 240-248, 1996.
23. 23. Pannek J, Subong ENP, Jones KA, et al: The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology 48: 51-54, 1996.
24. 24. Stein A, Barak M, Mecz Y, et al: Serum free/total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists. Eur Urol 32: 64-68, 1997.
25. 25. Berruti A, Fasolis G, Tarabuzzi R, et al: Circulating levels of free serum prostate specific antigen (fPSA) in advanced prostate cancer (PC) patients (abstract). Eur Urol 33(suppl): 46, 1998.
26. 26. Liu AY, True LD, LaTray L, et al: Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci 94: 10705-10710, 1997.
27. 27. Hayashi N, Tsuji M, Sugimura T, et al: Change in morphological and functional cytodifferentiation induced by seminal vesicle mesenchyme in cell suspensions of rat Dunning prostatic adenocarcinoma cells. Int J Cancer 68: 788-794, 1996.
28. 28. Mikolajczyk SD, Grauer LS, Millar LS, et al: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50: 710-714, 1997.
29. 29. Corey E, Brown LG, Corey MJ, et al: LNCaP produces both putative zymogen and inactive, free form of prostate specific antigen. Prostate 35: 135-143, 1998.
30. 30. Noldus J, Chen Z, and Stamey TA: Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 158: 1606-1609, 1997.